Clostridium Difficile Infection Treatment Market (By Drug Type: Vancomycin, Fidaxomicin, Metronidazole; By Administration: Oral, Injectable; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 190

The global clostridium difficile infection treatment market is anticipated to grow at a CAGR of around 5.8% during the forecast period 2020 to 2027 and to reach around US$ 1.4 Bn by 2027.

Market Dynamics

Major factors expected to drive the growth of the global market are increasing number of patients suffering from chronic diseases, coupled with introduction of innovative treatment from major players. According to U.S. Department of Health & Human Services in 2017, there were an estimated 223,900 cases in hospitalized patients suffering from clostridioides difficile infection and 12,800 deaths in the United States.

Government of developing countries focus on enhancing the healthcare R&D capabilities is resulting in adoption of advanced equipments along with high spending on drug discovery in order to provide novel drugs. Developing healthcare standards and high spending on infrastructure development in order to facilitate the adoption of advanced treatment is expected to boost the growth of target market.

In 2018, Xellia Pharmaceuticals, a leader in manufacturing of specialty anti-infective treatments launched Vancomycin Hydrochloride for Injection in the US market. This product launch is expected to help the company to strengthen its position in US market.

In 2016, Baxter International Inc. a global drug manufacturer launched VANCOMYCIN a ready-to-use injection in 0.9% Sodium Chloride. VANCOMYCIN injection is an antibiotic used to treat serious or severe bacterial infections. This is expected to help the company to enhance the customer base.

In 2017, Astellas Pharma Inc. a global drug company announced that it has sent approval for marketing of fidaxomicin that is for the treatment of infectious enteritis. This is expected to help the company to attract new customer and enhance the customer base.

In 2018, the company announced the launch of Dafclir® Tablets for the Treatment of Infectious Enteritis. This is an oral macrocyclic antimicrobial agent with a new mechanism of action and a selective antibacterial spectrum. This will help the company to increase the revenue share.

Increasing merger and acquisition activities by major players in order to strengthen its business presence and enhance the product portfolio are factors expected to positively impact the growth of target market. In addition, increasing public-private partnership for R&D activities is expected to support the growth of target market.

In 2017, Xellia Pharmaceuticals a pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, invested US$ 25 Mn for the expansion of its Copenhagen site. This is expected to help the company to enhance its product capabilities.

Flourishing healthcare sector in countries such as Singapore and Malaysia along with availability of advanced medical facilities at low cost and favorable insurance policies are factors expected to support the growth of target market.

However, factors such as high cost associated to R&D activities and stringent government regulation related to product approval are expected to hamper the growth of global clostridium difficile infection treatment market. In addition, low awareness related to CDI in developing countries is expected to challenge the growth of target market.

Rapid technological advancements by major players and introduction of novel treatments are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership and agreements between regional and international players is expected to revenue support the growth of target market.

Segment Analysis by Region

The market in North America is expected to account for significant revenue share owing to increasing number of patients suffering from chronic diseases. In addition presence of large number of players operating in the country and focus on introduction of innovative solution are factors expected to support the growth of target market.

Competitive Landscape                                                                                 

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market

Global Clostridium Difficile Infection Treatment Market

Analysis Period

2016 – 2027

Base Year

2019

Forecast Data

2020 – 2027

Market Stratification

Drug Type, Administration, Distribution Channel and Geography

Regional Scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Report Coverage

Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis


Clostridium Difficile Infection Treatment Market Segment Analysis, 2019

The global clostridium difficile infection treatment market is segmented into drug type, administration, and distribution channel. The administration segment is bifurcated into oral and injectable. Among administration the injectable segment is expected to witness faster growth in the near future due to high R&D activities by major players are introduction of innovative solutions. The distribution channel segment is divided into hospital pharmacies, retail pharmacies, and others. The hospital segment is expected to account for major revenue share in the global market. This is due to high government spending on development of hospital infrastructure.

The players profiled in the report are Baxter International Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd, Mylan, Novartis AG, Astellas Pharma, Merck and Co. Inc., Pfizer Inc., Eli Lilly and Company, AstraZeneca Plc.

Market Segmentation

Market By Drug Type

Vancomycin

Fidaxomicin

Metronidazole

Market By Administration

Oral

Injectable

Market By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

Market By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa


Frequently Asked Questions

The global clostridium difficile infection treatment market in 2027 is expected to be above US$ 1.4 Bn.

In distribution channel segment the hospital segment is growing at faster pace.

The CAGR of the global clostridium difficile infection treatment market from 2020-2027 is around 5.8%.

Major factors expected to drive the growth of the global market are increasing number of patients suffering from chronic diseases, coupled with introduction of innovative treatment from major players.

In the global market the Asia Pacific region is expected to grow faster.

Some of the players considered in the report scope are Astellas Pharma, Merck and Co. Inc., Pfizer Inc., Eli Lilly and Company, AstraZeneca Plc.

The North America is expected to account for major revenue share in the global market.

Cart Summary


60